Catumaxomab Completed Phase 2 Trials for Ovarian Cancer / Epithelial Ovarian Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0028213 (Ovarian Cancer) DBCOND0030546 (Epithelial Ovarian Cancer)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00563836	Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer	Catumaxomab (DB06607)